Key clinical trials of durvalumab (sponsored by AstraZeneca/MedImmune unless stated otherwise)
| Drug(s) | Indication | Phase | Status | Identifier |
|---|---|---|---|---|
| Durvalumab ± tremelimumab, SoC (1st line) | Stage IV urothelial carcinoma | III | Recruiting | NCT02516241; DANUBE |
| Durvalumab, SoC (1st line) | Advanced NSCLC | III | Recruiting | NCT03003962; PEARL |
| Durvalumab ± tremelimumab, SoC (1st line) | Advanced/metastatic NSCLC | III | Ongoing | NCT02453282; MYSTIC |
| Durvalumab + tremelimumab, SoC (1st line) | Advanced/metastatic NSCLC | III | Recruiting | NCT02542293; NEPTUNE |
| Durvalumab ± tremelimumab, SoC (3rd line) | Advanced/metastatic NSCLC | III | Ongoing | NCT02352948; ARCTIC |
| Durvalumab + concurrent chemoradiation | Stage III unresectable NSCLC | III | Ongoing | NCT02125461; PACIFIC |
| Durvalumab, placebo (adjuvant therapy) | Completely resected NSCLC | III | Recruiting | NCT02273375; ADJUVANTa |
| Durvalumab, multiple comparators (biomarker-targeted 2nd line) | Stage IV squamous NSCLC | II/III | Recruiting | NCT02154490; Lung Master Protocola |
| Durvalumab (3rd line) | Advanced/metastatic NSCLC | II | Ongoing | NCT02087423; ATLANTIC |
| Durvalumab ± tremelimumab + chemotherapy | Advanced SCLC | III | Recruiting | NCT03043872; CASPIAN |
| Durvalumab + tremelimumab, AZD1775 + carboplatin | Extensive stage SCLC | II | Recruiting | NCT02937818; BALTIC |
| Durvalumab ± tremelimumab, SoC (1st line) | Recurrent/metastatic HNSCC | III | Ongoing | NCT02551159; KESTREL |
| Durvalumab ± tremelimumab, SoC (2nd line) | Recurrent/metastatic HNSCC | III | Recruiting | NCT02369874; EAGLE |
| Durvalumab | Recurrent/metastatic HNSCC | II | Ongoing | NCT02207530; HAWK |
| Durvalumab, tremelimumab, durvalumab + tremelimumab | Recurrent/metastatic HNSCC | II | Ongoing | NCT02319044; CONDOR |
| Durvalumab + tremelimumab, durvalumab, tremelimumab | Unresectable hepatocellular carcinoma | II | Recruiting | NCT02519348 |
| Durvalumab + tremelimumab, durvalumab | Advanced solid tumours | III | Recruiting | NCT03084471; STRONG |
| Durvalumab | HIV-1 plus solid tumours | II | Recruiting | NCT03094286 |
| Durvalumab, tremelimumab, durvalumab + tremelimumab | Advanced solid tumours | II | Ongoing | NCT02527434 |
| Durvalumab (≥2nd line) | Advanced solid tumours | I/II | Ongoing | NCT01693562; Study 1108 |
All are multinational trials, with the exception of NCT03094286, which is being conducted in Spain
NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma, SCLC small cell lung cancer, SoC standard-of-care
aSponsored by Canadian Cancer Trials Group (ADJUVANT) or Southwest Oncology Group (Lung Master Protocol)